RxDoctor Payments Data

Eduardo Martinez, MD

Urogynecology and Reconstructive Pelvic Surgery · Miami, FLNPI 1891957940

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (44.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Boston Scientific at 32.7% of the total. Reporting peaked in 2023 at $2,117 and has fallen 92.3% since, to $163 in 2025.

$7,422in general payments, 2019–2025

Across 125 payments — averaging $59.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Intuitive Surgical$2K
  • Axonics, Inc.$1K
  • AbbVie$323
  • Sumitomo Pharma America, Inc.$195
  • Femselect Inc.$106
  • plus $799 from 22 others

What the payments were for

  • Travel & lodging$3,30845%
  • Food & beverage$2,61335%
  • Education$1,50020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,422 in reported general payments places this provider in the 60th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$22,033
Medicare patients
47
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron82$50,437
MyrbetriqMirabegron26$13,499
Estradiol142$6,366
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst136$1,447
Estradiol (Twice Weekly)Estradiol16$1,348
Metronidazole11$423
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet18$297
Clobetasol Propionate19$176
Ibuprofen31$116
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$104
Fluconazole19$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$195$50,43782 claims
Astellas Pharma US IncMyrbetriq$54$13,49926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →